Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Mosunetuzumab · 1 trial · 1 indication
The primary endpoint of the trial is the ctDNA clearance rate after mosunetuzumab treatment among the subset of patients in a PET/CT CR but with ctDNA+ at the end of 6 cycles of R-pola-mini-CHP. The rate will be calculated as the number of subjects ctDNA- after mosunetuzumab treatment among all patients treated with mosunetuzumab as part of the Fleming two-stage design.
| Arm | Type | Description |
|---|---|---|
| ctDNA positive | EXPERIMENTAL | Patients who have achieved a radiographic complete response (CR) on PET/CT, but have detectable ctDNA at the end of treatment with pola-R-mini-CHP will receive 6 cycles of mosunetuzumab consolidation. Patients who have achieved a CR with undetectable ctDNA will be observed. Patients with a partial response on PET/CT will be managed per protocol. |
| Name | Type | Description |
|---|---|---|
| Mosunetuzumab | DRUG | Mosunetuzumab consolidation therapy will consist of 6 cycles of IV mosunetuzumab at the standard ramp-up dosing (Day 1 1mg, Day 8 2mg, D15 60mg, C2D1 60mg, and 30mg on day 1 of the subsequent 21-day cycles) |
| ClonoSEQ | DEVICE | Patients with detectable ClonoSEQ at C6D1 who have a PET/CT that shows a CR will receive mosunetuzumab |
Inclusion Criteria 1. Patients aged greater than or equal to 70 years of age who are ineligible for full-intensity chemoimmunotherapy at the discretion of the treating investigator. If between the ages of 70-79, the reason for ineligibility should be documented in a clinical note. If 80 or older, t...
Mosunetuzumab is being studied as a consolidation treatment for older patients with Diffuse Large B-Cell Lymphoma (DLBCL) who have detectable circulating tumor DNA (ctDNA) at the end of treatment with Pola-R-mini-CHP. It is an investigational therapy currently in Phase 2 clinical development.
Mosunetuzumab targets MS4A1, CD3E, CD3G, and CD3D. It is classified as a binding agent, designed to interact with these molecular targets in the context of B-cell lymphoma treatment.
Mosunetuzumab is being developed by Adaptive Biotechnologies Corporation, a company traded on the stock exchange under the ticker ADPT. The drug is currently in Phase 2 clinical trials for Diffuse Large B-Cell Lymphoma.
Mosunetuzumab is in Phase 2 clinical development. It is an investigational drug, not yet approved by regulatory authorities, and is being evaluated in an ongoing clinical trial for patients with Diffuse Large B-Cell Lymphoma.
Mosunetuzumab is being evaluated in clinical trial NCT06828991, a Phase 2 study recruiting older patients with Diffuse Large B-Cell Lymphoma who have detectable ctDNA after Pola-R-mini-CHP treatment. The trial is enrolling 40 participants in the United States.
Yes, Mosunetuzumab is also known by the ChEMBL identifier CHEMBL4297788. This identifier is used in chemical and biological databases to reference the same compound.